Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer
Osamu Ishimoto(Sendai Kousei Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Takashi Ishida(Keio University), Yoshihiro Honda, Mitsuru Munakata(Fukushima Medical University)
Cited by 12
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695